Zusammenfassung
Hintergrund und Fragestellung
Frauen erkranken seltener an einem Harnblasenkarzinom, sind jedoch häufiger von fortgeschritteneren Tumorstadien und ungünstigeren Krankheitsverläufen betroffen. Es ist bis heute unklar, welche Ursachen für den aggressiveren Verlauf des Harnblasenkarzinoms bei der Frau verantwortlich sind.
Material und Methode
Mittels einer PubMed-Recherche wurden Original- und Übersichtsartikel in einem Zeitraum von 2004 bis 2022 ausgewertet.
Ergebnisse
Es ist am ehesten von einer multifaktoriellen Genese auszugehen. In der Literatur werden v. a. epidemiologische und klinische Aspekte als mögliche Ursachen genannt. Ferner werden in letzter Zeit zunehmend auch genetische und hormonelle Faktoren sowie die Rolle des Urobioms diskutiert.
Schlussfolgerungen
Durch eine frühere Diagnosestellung und bessere operative Therapie kann der onkologische Verlauf der Harnblasenkarzinomerkrankung der Frau günstig beeinflusst werden. Weitere Analysen der genetischen, hormonellen und mikrobiologischen Faktoren könnten neue Wege in der Prävention, Diagnostik und Therapie des Harnblasenkarzinoms eröffnen.
Abstract
Background and objectives
Although the incidence of bladder cancer among women is lower, they tend to more often have advanced disease at presentation with a more aggressive course. It is still unclear which factors are responsible for the poorer prognosis of bladder cancer in women.
Materials and methods
Original papers and reviews from 2004 until 2022 were identified in a PubMed search and evaluated.
Results
Multiple factors are likely responsible for the different courses of bladder cancer in women versus men. In the literature, epidemiologic and clinical aspects are discussed. Furthermore, genetic and hormonal causes and the role of the urobiome have been the focus of discussion more recently.
Conclusions
Earlier diagnosis and better surgical treatment could lead to a more favorable course of bladder cancer in women. Further analyses of genetic, hormonal, und microbiological factors could open new perspectives in the prevention, diagnosis, and treatment of bladder cancer.
Literatur
Andreassen BK, Grimsrud TK, Haug ES (2018) Bladder cancer survival: women better off in the long run. Eur J Cancer 95:52–58
Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F (2017) Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol 71:96–108
Bilski K, Dobruch J, Kozikowski M, Skrzypczyk MA, Oszczudłowski M, Ostrowski J (2020) Urobiome in gender-related diversities of bladder cancer. Int J Mol Sci 21:4488
Burge F, Kockelbergh R (2016) Closing the gender gap: Can we improve bladder cancer survival in women?—A systematic review of diagnosis, treatment and outcomes. Urol Int 97:373–379
Burger M, Catto JWF, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, Kassouf W, Kiemeney LA, La Vecchia C, Shariat S, Lotan Y (2013) Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 63:234–241
Chamie K, Litwin MS, Bassett JC, Daskivich TJ, Lai J, Hanley JM, Konety BR, Saigal CS (2013) Recurrence of high-risk bladder cancer. Cancer 119:3219–3227
Cumberbatch MGK, Jubber I, Black PC, Esperto F, Figueroa JD, Kamat AM, Kiemeney L, Lotan Y, Pang K, Silverman DT, Znaor A, Catto JWF (2018) Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018. Eur Urol 74:784–795
de Jong JJ, Boormans JL, van Rhijn BWG, Seiler R, Boorjian SA, Konety B, Bivalacqua TJ, Wheeler T, Svatek RS, Douglas J, Wright J, Dall’Era M, Crabb SJ, Efstathiou JA, van der Heijden MS, Mouw KW, Miyamoto DT, Lotan Y, Black PC, Gibb EA, Porten SP (2020) Distribution of molecular subtypes in muscle-invasive bladder cancer is driven by sex-specific differences. Eur Urol Oncol 3:420–423
Dobruch J, Daneshmand S, Fisch M, Lotan Y, Noon AP, Resnick MJ, Shariat SF, Zlotta AR, Boorjian SA (2016) Gender and bladder cancer: a collaborative review of etiology, biology, and outcomes. Eur Urol 69:300–310
Gakis G, Stenzl A (2013) Gender-specific differences in muscle-invasive bladder cancer: the concept of sex steroid sensitivity. World J Urol 31:1059–1064
Gakis G, Bruins HM, Cathomas R, Comperat EM, Cowan NC, van der Heijden AG, Hernández V, Linares Espinós EE, Lorch A, Neuzillet Y, Ribal MJ, Rouanne M, Thalmann GN, Veskimäe E, Witjes AJ (2020) European Association of Urology guidelines on primary urethral carcinoma—2020 update. Eur Urol Oncol 3:424–432
Gakis G, Perner S, Stenzl A, Renninger M (2022) The CAG-triplet in the androgen receptor gene and single-nucleotide polymorphisms in androgen pathway genes in patients with concomitant bladder and prostate cancer. Urol Oncol 40:198.e1–198.e8
Gakis G, Perner S, Stenzl A, Renninger M (2022) The role of single-nucleotide polymorphisms of the 8q24 chromosome region in patients with concomitant bladder and prostate cancer. Scand J Urol 56:126–130
Garg T, Pinheiro LC, Atoria CL, Donat SM, Weissman JS, Herr HW, Elkin EB (2014) Gender disparities in hematuria evaluation and bladder cancer diagnosis: a population-based analysis. J Urol 192:1072–1077
Gil D, Zarzycka M, Dulińska-Litewka J, Ciołczyk-Wierzbicka D, Lekka M, Laidler P (2019) Dihydrotestosterone increases the risk of bladder cancer in men. Human Cell 32:379–389
Gul ZG, Liaw CW, Mehrazin R (2021) Gender differences in incidence, diagnosis, treatments, and outcomes in clinically localized bladder and renal cancer. Urology 151:176–181
Henning A, Wehrberger M, Madersbacher S, Pycha A, Martini T, Comploj E, Jeschke K, Tripolt C, Rauchenwald M (2013) Do differences in clinical symptoms and referral patterns contribute to the gender gap in bladder cancer? BJU Int 112:68–73
Ide H, Inoue S, Miyamoto H (2017) Histopathological and prognostic significance of the expression of sex hormone receptors in bladder cancer: a meta-analysis of immunohistochemical studies. PLoS ONE 12(3):e174746
Janisch F, Shariat SF, Schernhammer E, Rink M, Fajkovic H (2019) The interaction of gender and smoking on bladder cancer risks. Curr Opin Urol 29:249–255
Kluth LA, Fajkovic H, Xylinas E, Crivelli JJ, Passoni N, Rouprêt M, Becker A, Comploj E, Pycha A, Holmang S, Gupta A, Lotan Y, Karakiewicz PI, Gontero P, Chun FK‑H, Fisch M, Scherr DS, Shariat SF (2013) Female gender is associated with higher risk of disease recurrence in patients with primary T1 high-grade urothelial carcinoma of the bladder. World J Urol 31:1029–1036
Kourbanhoussen K, McMartin C, Lodde M, Zlotta A, Bryan RT, Toren P (2021) Switching cancers: a systematic review assessing the role of androgen suppressive therapy in bladder cancer. Eur Urol Focus 7:1044–1051
Koutros S, Silverman DT, Baris D, Zahm SH, Morton LM, Colt JS, Hein DW, Moore LE, Johnson A, Schwenn M, Cherala S, Schned A, Doll MA, Rothman N, Karagas MR (2011) Hair dye use and risk of bladder cancer in the New England bladder cancer study. Int J Cancer 129:2894–2904
Krimphove MJ, Szymaniak J, Marchese M, Tully KH, D’Andrea D, Mossanen M, Lipsitz SR, Kilbridge K, Kibel AS, Kluth LA, Shariat SF, Trinh QD (2021) Sex-specific differences in the quality of treatment of muscle-invasive bladder cancer do not explain the overall survival discrepancy. Eur Urol Focus 7:124–131
Lucca I, Fajkovic H, Klatte T (2014) Sex steroids and gender differences in non-muscle invasive bladder cancer. Curr Opin Urol 24:500–505
Madeb R, Messing EM (2004) Gender, racial and age differences in bladder cancer incidence and mortality. Urol Oncol 22:86–92
Mancini M, Righetto M, Baggio G (2020) Spotlight on gender specific disparities in bladder cancer. Urologia 87:103–114
Marks P, Soave A, Shariat SF, Fajkovic H, Fisch M, Rink M (2016) Female with bladder cancer: What and why is there a difference? Transl Androl Urol 5:668–682
Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre M‑L, Luke JJ, Gajewski TF (2018) The commensal microbiome is associated with anti-PD‑1 efficacy in metastatic melanoma patients. Science 359:104–108
Pederzoli F, Ferrarese R, Amato V, Locatelli I, Alchera E, Lucianò R, Nebuloni M, Briganti A, Gallina A, Colombo R, Necchi A, Clementi M, Montorsi F, Mancini N, Salonia A, Alfano M (2020) Sex-specific alterations in the urinary and tissue microbiome in therapy-naïve urothelial bladder cancer patients. Eur Urol Oncol 3:784–788
Pichler R, Fritz J, Heidegger I, Oberaigner W, Horninger W, Hochleitner M (2017) Gender-related outcome in bladder cancer patients undergoing radical cystectomy. J Cancer 8:3567–3574
Radkiewicz C, Edgren G, Johansson ALV, Jahnson S, Häggström C, Akre O, Lambe M, Dickman PW (2019) Sex differences in urothelial bladder cancer survival. Clin Genitourin Cancer 18:26–34
Robert-Koch Institut (2021) Krebs in Deutschland
Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, Castro MAA, Gibb EA, Kanchi RS, Gordenin DA, Shukla SA, Sanchez-Vega F, Hansel DE, Czerniak BA, Reuter VE, Su X, de Sa Carvalho B, Chagas VS, Mungall KL, Sadeghi S, Pedamallu CS, Lu Y, Klimczak LJ, Zhang J, Choo C, Ojesina AI, Bullman S, Leraas KM, Lichtenberg TM, Wu CJ, Schultz N, Getz G, Meyerson M, Mills GB, McConkey DJ, Research Network TCGA, Weinstein JN, Kwiatkowski DJ, Lerner SP (2017) Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 171:540–556
Scheller T, Hofmann R, Hegele A (2019) Sex-related differences in urothelial cell carcinoma of the bladder in Germany. Cancer Manag Res 11:309–316
Shang Z, Li Y, Hsu I, Zhang M, Tian J, Wen S, Han R, Messing EM, Chang C, Niu Y, Yeh S (2016) Targeting estrogen/estrogen receptor alpha enhances bacillus Calmette-Guerin efficacy in bladder cancer. Oncotarget 7:27325–27335
Siegrist T, Savage C, Shabsigh A, Cronin A, Donat SM (2010) Analysis of gender differences in early perioperative complications following radical cystectomy at a tertiary cancer center using a standardized reporting methodology. Urol Oncol 28:112–117
Sonpavde G, Okuno N, Weiss H, Yu J, Shen SS, Younes M, Jian W, Lerner SP, Smith CL (2007) Efficacy of selective estrogen receptor modulators in nude mice bearing human transitional cell carcinoma. Urology 69:1221–1226
Tan TZ, Rouanne M, Tan KT, Huang RYJ, Thiery JP (2019) Molecular subtypes of urothelial bladder cancer: results from a meta-cohort analysis of 2411 tumors. Eur Urol 75:423–432
Uhlig A, Strauss A, Hosseini ASA, Lotz J, Trojan L, Schmid M, Uhlig J (2018) Gender-specific differences in recurrence of non-muscle-invasive bladder cancer: a systematic review and meta-analysis. Eur Urol Focus 4:924–936
Uhlig A, Hosseini ASA, Simon J, Lotz J, Trojan L, Schmid M, Uhlig J (2018) Gender specific differences in disease-free, cancer specific and overall survival after radical cystectomy for bladder cancer: a systematic review and meta-analysis. J Urol 200:48–60
Wu P, Zhang G, Zhao J, Chen J, Chen Y, Huang W, Zhong J, Zeng J (2018) Profiling the urinary microbiota in male patients with bladder cancer in China. Front Cell Infect Microbiol 8:167
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
G. Gakis und D. Weckermann geben an, dass kein Interessenkonflikt besteht.
Für diesen Beitrag wurden von den Autor/-innen keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.
Additional information
QR-Code scannen & Beitrag online lesen
Rights and permissions
About this article
Cite this article
Gakis, G., Weckermann, D. Geschlechtsassoziierte Unterschiede beim Harnblasenkarzinom. Urologie 61, 1060–1067 (2022). https://doi.org/10.1007/s00120-022-01914-4
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00120-022-01914-4